[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645208":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":20,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GPC3-targeted PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of GPC3-targeted probe and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: 18F-FDG PET\u002FCT and GPC3-targeted PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-FDG PET\u002FCT and GPC3-targeted PET\u002FCT","Participants will receive a single intravenous injection of 18F-FDG and 68Ga-GPC3, and undergo PET\u002FCT imaging within the specified time.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Haojun Chen","86 18659285282","leochen0821@foxmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],118.08187,24.47979,{"lat":43,"lon":42},[46,47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100645208",false,"NCT07677774","GPC3-Targeted PET\u002FCT in Hepatocellular Carcinoma","Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":60,"type":61},40,"ESTIMATED","INTERVENTIONAL",[64],"NA","The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET\u002FCT in patients with suspected or histologically\u002Fclinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET\u002FCT.",[67,68,9],"Hepatocellular Carcinoma (HCC)","Glypican-3",[70,68,9,71,72],"Hepatocellular Carcinoma","HCC","PET\u002FCT","2026-06-25",{"date":75,"type":76},"2026-07-01","ACTUAL",{"date":78,"type":76},"2026-05-01",{"date":80,"type":61},"2028-05-31",{"name":5,"class":6},1]